SCHEMBL16635861

SCHEMBL16635861

O=C(O)C1CCCCC1c1nc(-c2ccc(F)cc2)oc1Br

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.38
HPGD P15428 1/20 0.38
TP53 P04637 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
CTSK P43235 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
GAA P10253 1/20 0.36
TBXA2R P21731 1/20 0.36
HDAC6 Q9UBN7 2/20 0.36
HTR3A P46098 2/20 0.35
APAF1 O14727 1/20 0.35
POLB P06746 1/20 0.35
GRK2 P25098 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35
HTT P42858 1/20 0.35
HDAC1 Q13547 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
GPR119 Q8TDV5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16636350 0.86 SLC6A2 (0.45) SMN1; SMN2HPGDTP53CTSKKDM4E
SCHEMBL16636352 0.86 SLC6A2 (0.45) SMN1; SMN2HPGDTP53CTSKKDM4E
SCHEMBL16618101 0.80 CTSK (0.49) SMN1; SMN2HPGDTP53TAAR1CTSK
SCHEMBL16635678 0.76 CTSK (0.42) SMN1; SMN2TAAR1CTSKALDH1A1TRPV1
SCHEMBL16635827 0.76 CTSK (0.42) SMN1; SMN2TAAR1CTSKALDH1A1TRPV1
SCHEMBL16635790 0.76 HPGD (0.49) SMN1; SMN2HPGDTAAR1GAATBXA2R
SCHEMBL16635685 0.75 CTSK (0.54) HPGDTP53CTSKKDM4EALDH1A1
SCHEMBL16635996 0.75 CTSK (0.47) SMN1; SMN2HPGDTP53CTSKKDM4E
SCHEMBL16635997 0.75 CTSK (0.54) HPGDTP53CTSKKDM4EALDH1A1
SCHEMBL16635684 0.75 CTSK (0.47) SMN1; SMN2HPGDTP53CTSKKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015051479-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ SMN1; SMN2 4512/4885HPGD 3020/4885TP53 1934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.